Current Report Filing (8-k)
20 April 2017 - 5:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
___________________
FORM 8-K
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (date of earliest event reported):
April 12, 2017
OWC
P
harmaceutical
R
esearch
C
orp.
(Exact Name of
Registrant as Specified in its Charter)
Commission File No.: 0-54856
Delaware
|
98-0573566
|
(State of Incorporation)
|
(I.R.S. Employer Identification No.)
|
|
|
30 Shacham Street. P.O.B.
8324 Petach Tikva, Israel
|
4918103
|
(Address of Principal Executive Offices)
|
(ZIP Code)
|
Registrant's
Telephone Number, including area code: 972 (0) 3-758-2657
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On April 12, 2017, OWC Pharmaceutical Research Corp. (the
"Registrant") announced the appointment of Alon Sinai, Chief Operating
Officer of Registrant's wholly-owned Israeli subsidiary, One World Cannabis
Ltd ("OWC Israel") since July 2014, as the new Interim Chief Executive
Officer of OWC Israel, replacing Mr. Ziv Turner.
Alon Sinai, age 49, Chief Operating Officer and Interim Chief
Executive Officer of One World Cannabis Ltd, has served as OWC's liaison with
Israel's major medical institutions and teaching hospital, leading negotiations
for the establishment of OWC Israel's collaboration agreements and clinical
trial studies. Mr. Sinai is a retired Lieutenant-Colonel of the IDF who served
in its Medical Corps from 1987 to 2013. Mr. Sinai successfully completed the
NATO School Oberammergau Program, NATO's individual training and education
facility at the operational level. Mr. Sinai recently served as Head of the
Doctrine, Instruction and Training Department of the IDF, where he was
responsible for commanding and developing emergency medical facilities, writing
professional doctrine and literature for the IDF Medical Corps and working with
foreign militaries. Mr. Sinai is currently pursuing his Ph.D. in Health Systems
Management at Ben-Gurion University of the Negev, where he previously earned an
MA in Health Systems Management and a B.EMS in Emergency Medicine.
Mr. Turner has informed the Registrant that he intends to
pursue other business opportunities.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
OWC Pharmaceutical
Research Corp.
|
|
|
|
|
|
By:
/s/ Mordechai
Bignitz
|
|
|
Name: Mordechai Bignitz
|
|
|
Title: Chief Executive
Officer
|
|
Date: April 19, 2017
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Apr 2024 to May 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about OWC Pharmaceuticals Research Corporation (CE) (OTCMarkets): 0 recent articles
More Owc Pharmaceutical Research Corp. News Articles